DERM

News Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals

19d ago

SEC filing DERM Expands Emrosi™ GPO Coverage to 150M Lives, $150M+ Potential, 85% Commercial Access, Rosacea Market Push

41d ago

News Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand

68d ago

SEC filing DERM Reports $61.9M Revenue, $11.4M Net Loss, $2.9M Adjusted EBITDA, 53K Emrosi Scripts, $24.1M Cash

68d ago

News Fortis Inc. PREF SHS SER I declares CAD 0.2246 dividend

109d ago

News Fortis Inc. 1ST PFD SER F declares CAD 0.3063 dividend

109d ago

Scanner Unusual volume (z=4.3)

160d ago

Scanner Unusual volume (z=4.1)

161d ago

Scanner Unusual volume (z=4.1)

163d ago

Scanner Unusual volume (z=4.1)

164d ago